B
23.11
-0.36 (-1.53%)
| Previous Close | 23.47 |
| Open | 23.21 |
| Volume | 604,709 |
| Avg. Volume (3M) | 543,518 |
| Market Cap | 1,512,946,816 |
| Price / Book | 3.54 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Diluted EPS (TTM) | -1.69 |
| Total Debt/Equity (MRQ) | 0.13% |
| Current Ratio (MRQ) | 24.62 |
| Operating Cash Flow (TTM) | -88.27 M |
| Levered Free Cash Flow (TTM) | -53.72 M |
| Return on Assets (TTM) | -13.84% |
| Return on Equity (TTM) | -27.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Bicara Therapeutics Inc. | Bullish | Bearish |
AIStockmoo Score
-0.8
| Analyst Consensus | 2.0 |
| Insider Activity | -5.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.5 |
| Average | -0.80 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 11.65% |
| % Held by Institutions | 89.28% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HYEP IVAN | - | 23.11 | -9,200 | -212,612 |
| RABEN DAVID | - | 22.48 | -5,500 | -123,613 |
| Aggregate Net Quantity | -14,700 | |||
| Aggregate Net Value ($) | -336,225 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 22.79 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RABEN DAVID | Officer | 27 Apr 2026 | Automatic sell (-) | 5,500 | 22.48 | 123,613 |
| RABEN DAVID | Officer | 27 Apr 2026 | Option execute | 5,500 | - | - |
| HYEP IVAN | Officer | 21 Apr 2026 | Automatic sell (-) | 9,200 | 23.11 | 212,612 |
| HYEP IVAN | Officer | 21 Apr 2026 | Option execute | 9,200 | - | - |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |